Home ER stress & UPR Antioxidant chemical Edaravone For research use only.

Edaravone

Synonyms: MCI-186

Edaravone (MCI-186) is a novel potent free radical scavenger that has been clinically used to reduce the neuronal damage following ischemic stroke.

Edaravone Chemical Structure

Edaravone Chemical Structure

CAS: 89-25-8

Selleck's Edaravone has been cited by 6 publications

Purity & Quality Control

Batch: Purity: 99.89%
99.89

Related compound libraries

Choose Selective Antioxidant Inhibitors

Biological Activity

Description Edaravone (MCI-186) is a novel potent free radical scavenger that has been clinically used to reduce the neuronal damage following ischemic stroke.
In vitro
In vitro Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS). Edaravone, which inhibits oxidation and enhances NO production derived from increased eNOS expression, may improve and conserve cerebral blood flow without peroxynitrite generation during reperfusion. [1]
In Vivo
In vivo Edaravone significantly reduces the infarct volume and improves the neurological deficit scores at 24 hours after reperfusion in mice brain. Edaravone markedly suppresses the accumulation of HNE-modified protein and 8-OHdG at the penumbra area during the early period after reperfusion and reduces microglial activation, iNOS expression, and nitrotyrosine formation at the late period. [2] Edaravone attenuates renal function and pathologic findings significantly in rat kidney. Edaravone significantly reduces the generation of free radicals in the tubular cells indicated by dichlorodihydrofluorescein. [3] Edaravone-treated animals shows significantly improved neurological outcome. Edaravone-treatment provides a significant reduction in the number of TUNEL-positive apoptotic cells, a decrease in Bax immunoreactivity and an increase in Bcl-2 expression within the peri-infarct area. Edaravone shows an excellent neuroprotective effect against ischemia/reperfusion brain injury through a Bax/Bcl-2 dependent anti-apoptotic mechanism. [4]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06107205 Recruiting Healthy Adult Subjects Auzone Biological Technology Pty Ltd September 27 2023 Phase 1
NCT05953103 Recruiting Subjects With Cerebral Hemorrhage Simcere Pharmaceutical Co. Ltd July 3 2023 Phase 2
NCT05410457 Recruiting Ischemic Stroke Nanjing First Hospital Nanjing Medical University May 24 2022 --
NCT04776135 Completed Healthy Adult Subjects Mitsubishi Tanabe Pharma Corporation February 26 2021 Phase 1
NCT04254913 Completed Japanese Patients With ALS Mitsubishi Tanabe Pharma Corporation January 24 2020 Phase 1
NCT05342597 Completed Healthy Adult Subjects Mitsubishi Tanabe Pharma Corporation June 10 2019 Phase 1

Chemical lnformation & Solubility

Molecular Weight 174.2 Formula

C10H10N2O
CAS No. 89-25-8 SDF Download Edaravone SDF
Smiles CC1=NN(C(=O)C1)C2=CC=CC=C2
Storage (From the date of receipt) 3 years -20°C powder (seal)

In vitro
Batch:

DMSO : 35 mg/mL ( (200.91 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Edaravone | Edaravone ic50 | Edaravone price | Edaravone cost | Edaravone solubility dmso | Edaravone purchase | Edaravone manufacturer | Edaravone research buy | Edaravone order | Edaravone mouse | Edaravone chemical structure | Edaravone mw | Edaravone molecular weight | Edaravone datasheet | Edaravone supplier | Edaravone in vitro | Edaravone cell line | Edaravone concentration | Edaravone nmr